Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
NXE-0048149 by Nxera Pharma for Schizophrenia: Likelihood of Approval
NXE-0048149 is under clinical development by Nxera Pharma and currently in Phase I for Schizophrenia. According to GlobalData, Phase I...
Data Insights
NXE-0048149 by Nxera Pharma for Psychosis: Likelihood of Approval
NXE-0048149 is under clinical development by Nxera Pharma and currently in Phase I for Psychosis. According to GlobalData, Phase I...